GPA AND MPA


Associated tags: Health, Glucocorticoid, Anti-neutrophil cytoplasmic antibody, HS, Nephrology, MHRA, Prednisolone, Kidney, MPA, Fresenius Medical Care, GPA, Lung, Hidradenitis suppurativa, Microscopic polyangiitis, University, Cyclophosphamide, Regulation of tobacco by the U.S. Food and Drug Administration, Medicine, Food

Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)

Retrieved on: 
Thursday, August 18, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Vasculitis, Receptor (biochemistry), Multimedia, Dialysis, Risk, NICE, Inflammation, C5a, National Health Service, Population, Neutrophil, Failure, University of Cambridge, ANCA, Atypical hemolytic uremic syndrome, ASX, Rituximab, European Commission, Steroid, CSL, Patient, Quality of life, Marketing, Cell, Hidradenitis suppurativa, Granulomatosis with polyangiitis, Anti-neutrophil cytoplasmic antibody, HS, Nephrology, MHRA, Prednisolone, Kidney, MPA, Fresenius Medical Care, GPA, Glucocorticoid, Lung, Microscopic polyangiitis, University, Cyclophosphamide, Time, Regulation of tobacco by the U.S. Food and Drug Administration, Medicine, Food, Adult, AAV, Disease, Health care, Pharmaceutical industry

We very much welcome NICEs decision, which means that eligible patients and clinicians have another choice of treatment for this debilitating condition.

Key Points: 
  • We very much welcome NICEs decision, which means that eligible patients and clinicians have another choice of treatment for this debilitating condition.
  • NICEs decision represents a major advancement for the treatment of GPA/MPA in the UK, said Prof. David Jayne, Professor of Clinical Autoimmunity, University of Cambridge.
  • Patients will now have access to a new therapy option that could help them optimize their treatment outcomes.
  • Tavneos was developed by ChemoCentryx, Inc., who is also developing Tavneos for the treatment of patients with C3 Glomerulopathy (C3G) and hidradenitis suppurativa (HS).